Two hundred AI-designed drugs are now in human trials. Not one is approved.

Run time: 20:11

In today's episode:

1. Two hundred AI-discovered drugs in trials, zero approved
2. FDA clears Clarius bedside ejection-fraction AI
3. GE HealthCare auto-contouring tool cleared for radiation planning
4. Philips and WellSpan sign seven-year AI imaging alliance
5. Joint Commission launches first hospital AI certification
6. WHO weighs AI for health-policy decisions
7. Anthropic scales Mythos cyber program to fifteen countries
8. Perplexity lets its agent write its own search code
9. OpenAI says chat is dead, pivots to agents

TL;DR:

• The AI drug-discovery story matured into a counting problem: 200-plus candidates in clinical trials, roughly 56 in Phase 2 and 15 in Phase 3, and still zero FDA approvals. The 2026 Phase 3 readouts (zasocitinib, more rentosertib data) are the real test.
• Two more FDA clearances landed this week — Clarius for bedside ejection fraction, GE HealthCare for radiation-oncology auto-contouring — both narrow, both incremental, both shipping into existing workflows rather than replacing anyone.
• Governance caught up to deployment: the Joint Commission's Responsible Use of AI certification went live June 1, the first accreditation-grade AI program built specifically for health systems.

Sources cited:

• BioMed Nexus
• DAIC
• ITN
• Philips
• Joint Commission
• WHO
• TechCrunch
• The Decoder
• the AAPM TG-275/TG-132 segmentation guidance and reviews on auto-segmentation QA

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

Mayo Clinic just decided to build its own medical A.I. and own it outright.

Run time: 12:40

In today's episode:

1. Mayo Clinic and Microsoft build a frontier medical AI
2. FDA clears Philips Elevate Plus AI ultrasound
3. AI reads cancer from ordinary tissue slides
4. Patients start using AI scribes in the exam room
5. AI arms race is inflating medical billing
6. ARPA-H funds first FDA-authorized clinical AI agents
7. Eli Lilly fires up a thousand-GPU drug-discovery supercomputer
8. Anthropic confidentially files to go public
9. Google ships Gemma 4, a laptop-class multimodal model
10. Microsoft unveils MAI-Thinking-1 reasoning model

TL;DR:

• Mayo Clinic and Microsoft are co-building a healthcare-specific frontier model that Mayo will own and distribute via Azure Foundry — the most consequential "vertical foundation model" move yet in medicine.
• FDA cleared Philips Elevate Plus (AI ultrasound upgrade) and ARPA-H's ADVOCATE program is funding the first FDA-authorized agentic clinical AI — regulation is now actively shaping autonomous, not just diagnostic, AI.
• Anthropic confidentially filed an S-1 with the SEC (June 1), and Google shipped Gemma 4 12B, a multimodal model that runs locally on 16GB laptops.

Sources cited:

• Microsoft / Mayo
• Philips
• QIMR Berghofer / Nature Communications
• STAT
• STAT
• ARPA-H
• Healthcare context / NVIDIA
• Anthropic
• Hipther AI Dispatch
• Nature Communications, "Robust and interpretable prediction of gene markers and cell types from spatial transcriptomics data"

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

Taiwan just put one and a half billion dollars behind robot nurses in real operating rooms.

Run time: 20:53

In today's episode:

1. Taiwan and Foxconn launch 1.5 billion dollar clinical AI push
2. Coalition for Health AI ships 8 governance playbooks
3. BostonGene brings 9 AI biomarker abstracts to ASCO
4. Roswell Park flags limits of AI clinical decision support
5. Lancet Digital Health audits fairness metrics in clinical AI
6. Dana-Farber lands two plenaries at ASCO 2026
7. Anthropic splits programmatic Claude usage into credits
8. NVIDIA unveils RTX Spark personal AI superchip

TL;DR:

• Embodied AI moves from concept to a sovereign-scale deployment: NVIDIA, Foxconn, and Taiwan's hospital network commit $1.5B to put agentic and physical AI into real ORs and wards.
• CHAI publishes the most comprehensive open governance playbooks yet — eight modules for 100+ US health systems, mapped to the Joint Commission's coming AI certification.
• ASCO 2026 day three turns into AI day: BostonGene, Roswell Park, Dana-Farber, and a dedicated 4:30 PM AI session put oncology AI into the plenary spotlight.

Sources cited:

• source
• source
• source
• source
• source
• source
• source
• source
• source
• source

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

ASCO twenty twenty-six opens today, and AI just lifted lung-cancer biomarker testing by twenty-four percent.

Run time: 19:27

In today's episode:

1. Tempus Next lifts lung-cancer biomarker testing by twenty-four percent
2. Mayo Clinic brings thirty oncology AI studies to ASCO
3. Sylvester AI reads bone marrow to personalize myeloma therapy
4. Penn Medicine flags AI gaps in patient cancer info
5. NEJM AI publishes MEDS open data standard for health AI
6. Anthropic ships Claude Opus four point eight with dynamic workflows
7. Anthropic in talks to raise sixty-five billion at nine-hundred-sixty-five billion
8. Mythos moves toward broader release after ten thousand bugs found

TL;DR:

• ASCO 2026 kicks off in Chicago today — Tempus Next's AI clinical decision support lifted real-world biomarker-testing rates by +24% ALK, +18% EGFR, +13% PD-L1 in early-stage NSCLC across six community health systems, a rare deployed-AI outcomes win.
• Anthropic released Claude Opus 4.8 yesterday — high-effort default, dynamic workflows spawning hundreds of parallel subagents, agentic coding jumps 64.3→69.2%, ~4× fewer flawed-code passes, fast mode 3× cheaper. Pricing held at $5/$25 per M tokens.
• NEJM AI published the MEDS (Medical Event Data Standard) review on May 28 — an open data framework now used at 21 institutions and 27 papers that aims to fix reproducibility/portability in EHR-based clinical AI.

Sources cited:

• businesswire
• Mayo News Network
• Newswise
• Penn Medicine
• NEJM AI
• Harvard Science Review
• Anthropic
• TechCrunch
• US News
• MEDS overview

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

The FDA just cleared the first AI that reads burn wounds.

Run time: 20:51

In today's episode:

1. FDA grants De Novo clearance to burn-reading AI
2. Eli Lilly puts five hundred million into Korean AI lab
3. QIAGEN and NVIDIA team up on AI drug discovery
4. Bristol Myers Squibb rolls Claude to thirty thousand staff
5. Abu Dhabi and J&J launch AI surgical network
6. Artera takes multimodal cancer AI to ASCO
7. Twin Health launches AI for GLP-1 stewardship
8. Lancet study: ChatGPT discharge summaries boost patients
9. Claude adds twenty-eight security and compliance tools
10. DeepMind hires twenty researchers from Contextual AI

TL;DR:

• The FDA granted De Novo clearance to Spectral AI's DeepView — the first AI burn-wound assessment system, opening a brand-new device category for multispectral imaging in trauma and burn care.
• The pharma-AI operating model deepened in one week: Eli Lilly committed $500M to a Korean AI drug-discovery hub, QIAGEN tied up with NVIDIA on BioNeMo-powered target ID, and Bristol Myers Squibb put Claude in front of ~30,000 employees.
• Anthropic launched the Claude Compliance API with 28 enterprise security integrations (CrowdStrike, Microsoft Purview, Wiz, Okta, Zscaler, Cloudflare and more) — the missing governance layer hospitals and pharma IT have been waiting on.

Sources cited:

• GlobeNewswire
• Dong-A Science
• Digital Health News
• Digital Health News
• Gulf News
• BusinessWire
• HIT Consultant
• The Lancet Digital Health
• Help Net Security
• HeyGoTrade

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

FDA cleared does not mean it actually works. Today, the proof.

Run time: 16:28

In today's episode:

1. AZmed's X-ray AI clears fractures, effusions, dislocations
2. FDA clears first digital-pathology breast cancer risk tool
3. Radiologist-plus-AI beats AI alone for clot detection
4. Top journal: FDA cleared isn't FDA proven
5. Ultromics raises 55 million for echo AI
6. FDA now clears an AI device every 31 hours
7. KPMG puts Claude in front of 276,000 staff
8. Anthropic eyes 900-billion valuation, may pass OpenAI
9. Microsoft's 100 agents find 16 Windows flaws
10. xAI ships Grok Build, its first coding agent

TL;DR:

• A fresh wave of FDA clearances (AZmed's AZtrauma for fractures/effusions/dislocations; ArteraAI Breast) lands the same week a top journal warns that "cleared" is not "clinically proven" — the procurement question from yesterday's lung-CXR head-to-head is now everyone's problem.
• KPMG is rolling Claude out to 276,000+ employees as Anthropic courts a $30B raise at a $900B+ valuation that could top OpenAI for the first time.
• New peer-reviewed data shows radiologists plus AI beat AI alone at finding pulmonary embolism — the week's quiet through-line is collaboration and evidence, not replacement.

Sources cited:

• Diagnostic Imaging
• Artera
• AuntMinnie
• Annals of Internal Medicine
• Crescendo AI Healthcare News
• Innolitics 510(k) Year-in-Review
• Anthropic
• Bloomberg
• Microsoft Security Blog
• The Decoder

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

A saliva test just flagged cancer in under ten minutes.

Run time: 20:23

In today's episode:

1. Hong Kong saliva device flags cancer in minutes
2. AI risk scores failed to change transplant talks
3. ARPA-H funds a behavioral-health foundation model
4. Lawsuits hit AI scribes over recorded consent
5. AI avatar calmed cancer patients before treatment
6. METiS TechBio lists on AI nanomedicine bet
7. AI matches MS patients to a repurposed drug
8. Karpathy leaves OpenAI orbit, joins Anthropic
9. Google I/O ships Gemini 3.5, Omni, and Spark
10. Claude agents get self-hosted sandboxes and MCP tunnels
11. Cursor's Composer 2.5 matches Opus 4.7

TL;DR:

• A portable HKU device reads DNA-damage signals in saliva and returns a cancer-risk result via phone app in under 10 minutes — a potential cheap, non-invasive triage layer.
• A German RCT (PRIMA-AI) found that giving physicians AI graft-loss risk scores did NOT increase the rare-but-critical conversations about options after transplant failure — a clean reminder that prediction ≠ behavior change.
• Two AI-lab blockbusters landed: Andrej Karpathy joined Anthropic's pre-training team (May 19), and Google I/O unveiled Gemini 3.5 Flash, Gemini Omni (video), and the Gemini Spark agent.

Sources cited:

• HKU
• LucidQuest digest
• PR Newswire
• Fisher Phillips
• TechCrunch
• CNBC
• the-decoder
• Effective context engineering for AI agents

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

Most hospitals running AI agents have no idea if they actually work.

Run time: 20:30

In today's episode:

1. Only 59 percent of health orgs track their AI agents
2. Qure.ai Aira deployed across Mozambique's national health system
3. Annalise.ai goes network-wide at Parkway Singapore
4. Nature Medicine: clinical trials for self-updating AI
5. Nature Medicine: the AI co-scientist arrives in the clinic
6. Google Health Coach launches tomorrow on Gemini
7. Anthropic Code with Claude London hits tomorrow
8. Anthropic briefs finance regulators on Claude Mythos risks

TL;DR:

• Healthcare IT Today's May 17 industry digest surfaced two governance numbers worth pinning above every CIO's desk: only 59% of healthcare orgs actively track the performance of their AI agents in production, and 60% of nurses say they lack confidence in their organization's AI oversight — a credibility gap that lands the same week as Aidoc's CARE foundation model and Bayesian Health's continuous-sepsis monitor scale clinically.
• Nature Medicine published "Clinical trials for continuously monitored and updated AI systems" by van Amsterdam, Oberst, Feng et al., proposing a conceptual framework that separates AI-intrinsic monitoring/updating from trial-oversight monitoring — the methodological companion to last week's Frontiers in Science manifesto on adaptive surgical robots and the FDA's real-time trials pilot.
• VillageReach and Qure.ai have deployed Aira — Qure.ai's LLM-powered co-pilot for community health workers — across Mozambique's national health system under a Gates Foundation pandemic-preparedness grant, embedding it in the AlôVida hotline and PHEOC for early signal detection across primary care; pairs with last week's Anthropic-Gates $200M deal on neglected diseases.

Sources cited:

• Healthcare IT Today
• VillageReach announcement
• IHH Healthcare
• Nature Medicine
• Nature Medicine
• TechCrunch
• Claude.com
• Let's Data Science

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

Anthropic just put two hundred million dollars into AI for diseases pharma forgot.

Run time: 21:22

In today's episode:

1. Anthropic-Gates put $200M into Claude for neglected diseases
2. Frontiers in Science manifesto on adaptive surgical robots
3. Nature Medicine asks is AI actually improving care
4. Companion Nature Medicine piece on meaningful AI evaluation
5. npj Digital Medicine: RL boosts LLM radiology accuracy
6. medRxiv preprint on AI literacy micro-credentials
7. Claude for Small Business launches with fifteen workflows
8. PwC adopts Claude for enterprise deal execution

TL;DR:

• Anthropic and the Gates Foundation announced a four-year, $200M partnership on May 14 — the headline medical pillar is Claude usage credits for research centers hunting drug candidates in HPV and preeclampsia, two indications big pharma has long skipped.
• Nature Medicine's May issue keeps hammering the same theme it opened the year with: "Is AI actually improving healthcare?" and a companion methodology piece argue static benchmarks are misleading and most deployed medical AI still lacks evidence of attributable clinical benefit.
• A Frontiers in Science consensus piece from Dasgupta and Granados (King's College London) calls for an entirely new regulatory pathway for adaptive surgical robots that "continue to learn and change after approval" — a direct shot at how FDA and notified bodies currently classify SaMD.

Sources cited:

• Tech Startups
• Anthropic news
• Frontiers in Science
• Nature Medicine
• Nature Medicine
• npj Digital Medicine
• medRxiv preprint
• Anthropic news

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.

Roche just paid seven hundred fifty million dollars for an AI pathology company.

Run time: 21:10

In today's episode:

1. Roche acquires PathAI in nine-figure pathology AI deal
2. ISMRM 2026 unveils whole-body MRI and AI risk models
3. OpenAI publishes healthcare AI policy blueprint
4. AccurKardia gets FDA clearance for next-gen ECG AI
5. OpenEvidence embeds in Mount Sinai Epic at twelve billion valuation
6. Oracle Health Clinical AI Agent expands to thirty-plus specialties
7. Insilico signs two point seven five billion dollar Lilly discovery pact
8. Claude Managed Agents can now dream between sessions
9. Anthropic and SpaceX strike three-hundred-megawatt compute deal
10. Anthropic doubles Claude Code rate limits across paid tiers

TL;DR:

• Roche is acquiring PathAI for $750M upfront plus up to $300M in milestones, the first nine-figure pharma takeout of a pathology-AI pure-play and a sign foundation pathology models are becoming pharma infrastructure.
• ISMRM 2026 (Cape Town, May 9–14) is showcasing AI on whole-body MRI for early metabolic disease and quantitative MRI that matches mammography for dense-breast assessment — the next axis for image-based risk stratification.
• Anthropic shipped a research-preview "dreaming" feature for Claude Managed Agents on May 6: agents review past sessions between runs to update shared memory. Harvey reports roughly 6× task-completion gains.

Sources cited:

• source
• source
• source
• source
• source
• source
• source
• source
• source
• source

Subscribe: YouTube

medAI Times is for educational and informational purposes only. The content does not constitute medical advice, diagnosis, treatment recommendation, or professional clinical guidance. Consult qualified healthcare professionals and refer to official sources before making clinical, research, regulatory, or business decisions.